Regulus Therapeutics Inc. (RGLS) Set to Announce Earnings on Tuesday
Regulus Therapeutics Inc. (NASDAQ:RGLS) is set to release its earnings data after the market closes on Tuesday, November 7th. Analysts expect Regulus Therapeutics to post earnings of ($0.17) per share for the quarter.
Regulus Therapeutics (NASDAQ:RGLS) last announced its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.10). The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.02 million. Regulus Therapeutics had a negative net margin of 31,460.47% and a negative return on equity of 173.20%. On average, analysts expect Regulus Therapeutics to post $-0.97 EPS for the current fiscal year and $-0.38 EPS for the next fiscal year.
Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) traded up 1.9900% during mid-day trading on Wednesday, reaching $1.0199. 62,800 shares of the company’s stock were exchanged. The firm’s market capitalization is $105.85 million. Regulus Therapeutics Inc. has a one year low of $0.79 and a one year high of $3.38. The stock has a 50-day moving average of $1.27 and a 200 day moving average of $1.21.
RGLS has been the subject of several recent research reports. Zacks Investment Research raised Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.00 price objective for the company in a research report on Wednesday, July 12th. Needham & Company LLC reissued a “hold” rating on shares of Regulus Therapeutics in a research report on Wednesday, August 2nd. Chardan Capital lowered Regulus Therapeutics from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 2nd. Finally, Wedbush reissued an “ourperform” rating and set a $4.00 price objective on shares of Regulus Therapeutics in a research report on Monday, August 7th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the company’s stock. Regulus Therapeutics has a consensus rating of “Hold” and an average target price of $3.67.
Regulus Therapeutics Company Profile
Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.
Receive News & Ratings for Regulus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.